This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human Carbonic Anhydrase IX / CA9 (138-414) Protein, His Tag (MALS verified)
catalog :
CA9-H5220
quantity :
50 ug, 1 mg
price :
350 USD, 2400 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CA9-H5220
product name :
Human Carbonic Anhydrase IX / CA9 (138-414) Protein, His Tag (MALS verified)
quantity :
50 ug, 1 mg
price :
350 USD, 2400 USD
quantity & price :
$350/50ug,$2400/1mg
target :
Carbonic Anhydrase IX
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human Carbonic Anhydrase IX (138-414), His Tag (CA9-H5220) is expressed from human 293 cells (HEK293). It contains AA Gln 138 - Asp 414 (Accession # NP_001207.2).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human Carbonic Anhydrase IX (138-414), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant. Contact us for customized product form or formulation.
Storage :
Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● The product MUST be stored at -70°C or lower upon receipt;
● -70℃ for 3 months under sterile conditions.
Background :
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes. CAs form a family of enzymes that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate and protons (or vice versa), a reversible reaction that occurs rather slowly in the absence of a catalyst. One of the functions of the enzyme in animals is to interconvert carbon dioxide and bicarbonate to maintain acid-base balance in blood and other tissues, and to help transport carbon dioxide out of tissues. The active site of most carbonic anhydrases contains a zinc ion. There are at least five distinct CA families (α, β, γ, δ and ε).
Carbonic anhydrase 9 (CA9 / CAIX) is also known as Membrane antigen MN (MN), Renal cell carcinoma-associated antigen G250, which belongs to the alpha-carbonic anhydrase family. CA9 / CAIX with an optimal activity at pH 6.49. Reversible hydration of carbon dioxide. CA IX participates in pH regulation. CA9 may be involved in the control of cell proliferation and transformation. CA-IX appears to be a novel specific biomarker for a cervical neoplasia.
References :
(1) Badger MR, Price GD, 1994, Annu. Rev. Plant Physiol. Plant Mol. Bio. 45: 369–392.
(2) Temperini C., et al., 2007, Bioorg. Med. Chem. Lett. 17:2210-2215.
(3) Hilvo M., et al., 2008, J. Biol. Chem. 283:27799-27809.
(4) Alterio V., et al., 2009, Proc. Natl. Acad. Sci. U.S.A. 106:16233-16238.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments